Sexuality and climacteric: a comprehensive approach
Article Sidebar
Main Article Content
Abstract
When we talk about human sexuality, we know that we are talking about a complex and changing interaction between biological and socioemotional factors, which are highly influenced by society, family, religion and cultural norms. This can be seen in men and women especially in women Sexuality is an intuitive concept difficult to define. According to the World Health Organization, it is defined as “A state of physical, emotional, mental and social well being related to sexuality, which is not merely the absence of disease, dysfunction or disabilityˮ. It is a definition that takes into account several concepts, all very important. Sexual response is a series of neurophysiological, hemodynamic and hormonal changes involving the whole body. While similar in both sexes, women are not always the onset and progression correlate systematically or linearly as in men. And that intriguing evolution of the female sexual response, the difficulty of diagnosis of “female sexual dysfunctionˮ. We could summarize it in “a group of disorders in which the physiological or psychological problems impede participation or satisfaction in sexual activities; which results in the inability of a person to participate in a sexual relationship the way she or he would like to do itˮ16. Menopause is perceived by many women as to the end of sexuality, not only as the end of reproductive life. Sexual activity declines with age, and may be affected by a number of hormonal, psychological and sociocultural factors, but, for most women it continues to be important. We must understand that female sexual dysfunction, at any stage of life is multicausal and multidimensional. When approaching a patient, it is important to know all the factors that are involved, and which tools we have for deal with it. Classically, the therapeutic approach has consisted of psychological therapy and hormone therapy. However, we have to consider a recently approved drug by the FDA for the treatment of hypoactive sexual desire in women: Flibanserin. It is a psychotropic substance that acts on the mediators of sexual desire on the central nervous system favoring it.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
González Correales R. Los médicos y la sexualidad: una breve revisión histórica. En: Gándara JJ de la, Puigvert A. Sexualidad humana, una aproximación integral. Madrid: Médica Panamericana; 2005. p. 123-36.
Weinstein L, Swartz MN. Pathologic properties of invading microorganisms. En: Sodeman WA Jr, Sodeman WA, (eds). Pathologic physiology: mechanisms of disease, Vol. 1. Philadelphia: WB Saunders; 1974. p. 457-72.
Blumel Méndez JE, Castelo-Branco Flores C, Vallejo Maldonado S. La sexualidad en las diferentes etapas de la vida. En: Gándara JJ de la, Puigvert A. Sexualidad humana, una aproximación integral. Madrid: Médica Panamericana; 2005. p. 55-63.
World Health Organization. Education and treatment in human sexuality: the training of health professionals. Geneva: the Organization; 1975. (WHO Technical Report Series N° 572).
Nappi RE. Why are there no FDA-approved treatments for female sexual dysfunction? Expert Opin Pharmacother. 2015;16(12):1735-8 DOI: https://doi.org/10.1517/14656566.2015.1064393
World Health Organization. Defining sexual health: report of a technical consultation on sexual health, 28-31 January 2002. Geneva: the Organization; 2006.
Thornton K, Chervenak J, Neal-Perry G. Menopause and Sexuality. Endocrinol Metab Clin North Am. 2015;44(3):649-61. DOI: https://doi.org/10.1016/j.ecl.2015.05.009
Naeinian MR, Shaeiri MR, Hosseini FS. General health and quality of life in patients with sexual dysfunctions. Urol J. 2011;8(2):127-31.
Tepavcevic DK, Kostic J, Basuroski ID, et al. The impact of sexual dysfunction on the quality of life measured by MSQoL-54 in patients with multiple sclerosis. Mult Scler. 2008;14(8):1131-6. DOI: https://doi.org/10.1177/1352458508093619
Masters y Johnson [Internet]. En: Psicosexualidad. Blog del equipo de investigación “Salud, sexualidad y género”. [Vigo]: Universidad de Vigo; 2009 ago 15 [Consulta: 23/12/15]. Disponible en: http://psicosexualidadourense.blogspot.com.ar/2009/08/masters-y-johnson.html
Rosen RC, Barsky JL. Normal sexual response in women. Obstet Gynecol Clin North Am. 2006;33(4):515-26. DOI: https://doi.org/10.1016/j.ogc.2006.09.005
Kaplan HS. Disorders of sexual desire and other new concepts and techniques in sex therapy. New York: Brunner/Haze; 1979.
Gutiérrez Teira B. La respuesta sexual humana. AMF. 2010;6(10):543-6.
Basson R. Women’s sexual dysfunction. Revised and expanded definitions. CMAJ. 2005;172(10):1327-33. DOI: https://doi.org/10.1503/cmaj.1020174
Basson R, Brotto LA, Laan E, et al. Assessment and management of women's sexual dysfunctions: problematic desire and arousal. J Sex Med. 2005;2(3):291-300. DOI: https://doi.org/10.1111/j.1743-6109.2005.20346.x
Sánchez Hernández J, Monje Hernández E, Gándara Martín JJ de la. Disfunción sexual femenina. En: Gándara JJ de la, Puigvert A. Sexualidad humana, una aproximación integral. Madrid: Médica Panamericana: 2005. p. 140-5.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013. DOI: https://doi.org/10.1176/appi.books.9780890425596
Speroff L. The menopause: a signal for the future. En: Lobo R. Treament of the postmenopausal woman: basic and clinical aspects. 2th ed. Philadelphia: Lippincott Williams & Wilkins; 1999. p. 1-10.
Stahl SM. Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. CNS Spectr. 2015;20(1):1-6. DOI: https://doi.org/10.1017/S1092852914000832
Cain VS, Johannes CB, Avis NE, et al. Sexual functioning and practices in a multi-ethnic study of midlife women: baseline results from SWAN. J Sex Res. 2003;40(3):266-76. DOI: https://doi.org/10.1080/00224490309552191
Dennerstein L, Hayes RD. Confronting the challenges: epidemiological study of female sexual dysfunction and the menopause. J Sex Med. 2005;2 Suppl 3:118-32. DOI: https://doi.org/10.1111/j.1743-6109.2005.00128.x
Hällström T, Samuelsson S. Changes in women's sexual desire in middle life: the longitudinal study of women in Gothenburg. Arch Sex Behav. 1990;19(3):259-68. DOI: https://doi.org/10.1007/BF01541551
Lonnèe-Hoffmann RA, Dennerstein L, Lehert P, et al. Sexual function in the late postmenopause: a decade of follow-up in a population-based cohort of Australian women. J Sex Med. 2014;11(8):2029-38. DOI: https://doi.org/10.1111/jsm.12590
Burri A, Hilpert P, Spector T. Longitudinal evaluation of sexual function in a cohort of pre- and postmenopausal women. J Sex Med. 2015;12(6):1427-35 DOI: https://doi.org/10.1111/jsm.12893
North American Menopause Society. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society.Menopause. 2005;12(5):496-511; quiz 649. DOI: https://doi.org/10.1097/01.gme.0000177709.65944.b0
Shifren JL, Monz BU, Russo PA, et al. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112(5):970-8. DOI: https://doi.org/10.1097/AOG.0b013e3181898cdb
Leiblum SR, Koochaki PE, Rodenberg CA, et al. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). Menopause. 2006;13(1):46-56. DOI: https://doi.org/10.1097/01.gme.0000172596.76272.06
Lindau ST, Schumm LP, Laumann EO, et al. A study of sexuality and health among older adults in the United States. N Engl J Med. 2007;357(8):762-74. DOI: https://doi.org/10.1056/NEJMoa067423
Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009;6(8):2133-42. DOI: https://doi.org/10.1111/j.1743-6109.2009.01335.x
Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281(6):537-44. Erratum in: JAMA 1999;281(13):1174. DOI: https://doi.org/10.1001/jama.281.6.537
Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888-902; quiz 903-4. DOI: https://doi.org/10.1097/GME.0b013e3182a122c2
Kingsberg SA, Wysocki S, Magnus L, y col. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of TreatmentOptions for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790-9. DOI: https://doi.org/10.1111/jsm.12190
Genazzani AR, Gambacciani M, Simoncini T. Menopause and aging, quality of life and sexuality. Climacteric. 2007 Apr;10(2):88-96. DOI: https://doi.org/10.1080/13697130701297760
Avis NE, Colvin A, Bromberger JT, et al. Change in health-related quality of life over the menopausal transition in a multiethnic cohort of middle-aged women: Study of Women's Health Across the Nation. Menopause. 2009;16(5):860-9 DOI: https://doi.org/10.1097/gme.0b013e3181a3cdaf
Basson R, Wierman ME, van Lankveld J, et al. Summary of the recommendations on sexual dysfunctions in women. J Sex Med. 2010;7(1 Pt 2):314-26. DOI: https://doi.org/10.1111/j.1743-6109.2009.01617.x
SAEGRE. Guía Práctica para el Tratamiento de la Mujer durante el Climaterio. Lombardi y colaboradores, 18 de junio de 2005[MyF1].
Althof SE. Sex therapy and combined (sex and medical) therapy. J Sex Med. 2011;8(6):1827-8. DOI: https://doi.org/10.1111/j.1743-6109.2011.02306.x
Wierman ME, Nappi RE, Avis N, et al. Endocrine aspects of women's sexual function. J Sex Med. 2010;7(1 Pt2):561-85. DOI: https://doi.org/10.1111/j.1743-6109.2009.01629.x
Castelo-Branco Flores C, García García S. Papel del tratamiento hormonal sobre la sexualidad en la mujer postmenopáusica. En: Gándara JJ de la, Puigvert A. Sexualidad humana, una aproximación integral. Madrid: Médica Panamericana: 2005. p. 339-48.
Albertazzi P, Di Micco R, Zanardi E. Tibolone: a review. Maturitas. 1998;30(3):295-305. DOI: https://doi.org/10.1016/S0378-5122(98)00059-0
Reis BF, Lima SM, Silva GM, et al. Effects of low dose of tibolone on steroid receptors and Bcl-2 on the postmenopausal endometrium. Histol Histopathol. 2016;31(6):629-34.
Laan E, van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric. 2001;4(1):28-41. DOI: https://doi.org/10.1080/cmt.4.1.28.41
Egarter C, Topcuoglu A, Vogl S, et al. Hormone replacement therapy with tibolone: effects on sexual functioning in postmenopausal women. Acta Obstet Gynecol Scand. 2002;81(7):649-53. DOI: https://doi.org/10.1034/j.1600-0412.2002.810711.x
Ziaei S, Moghasemi M, Faghihzadeh S. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. Climacteric. 2010;13(2):147-56. DOI: https://doi.org/10.3109/13697130903009195
Davison SL, Bell R, Donath S, et al. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab. 2005;90(7):3847-53. DOI: https://doi.org/10.1210/jc.2005-0212
Labrie F, Martel C, Balser J. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? Menopause. 2011;18(1):30-43. DOI: https://doi.org/10.1097/gme.0b013e3181e195a6
Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489-510. DOI: https://doi.org/10.1210/jc.2014-2260
Panjari M, Davis SR. DHEA therapy for women: effect on sexual function andwellbeing. Hum Reprod Update. 2007;13(3):239-48. DOI: https://doi.org/10.1093/humupd/dml055
Elraiyah T, Sonbol MB, Wang Z, et al. Clinical review: The benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99(10):3536-42. DOI: https://doi.org/10.1210/jc.2014-2261
Gellad WF, Flynn KE, Alexander GC. Evaluation of Flibanserin: Science and Advocacy at the FDA. JAMA. 2015;314(9):869-70 DOI: https://doi.org/10.1001/jama.2015.8405
Nappi RE. Why are there no FDA-approved treatments for female sexual dysfunction? Expert Opin Pharmacother. 2015;16(12):1735-8. DOI: https://doi.org/10.1517/14656566.2015.1064393
Flibanserin, a medical treatment for female hypoactive sexual desire disorder [Internet]. [Consulta: 23/12/15]. Disponible en: http://www.flibanserin-hsdd.com/.
Joffe HV, Chang C, Sewell C, et al. FDA approval of flibanserin. Treating hypoactive sexual desire disorder. N Engl J Med. 2016;347(2):101-4. DOI: https://doi.org/10.1056/NEJMp1513686
U.S. Food and Drug Administration. FDA approves first treatment for sexual desire disorder: Addyi approved to treat premenopausal women [Internet]. Silver Spring. MD: U.S. Food and Drug Administration; 2015 Aug 18 [Consulta: 23/12/15]. Disponible en: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm458734.htm